These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 21067271)
21. Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells. Xia TS; Shi JP; Ding Q; Liu XA; Zhao Y; Liu YX; Xia JG; Wang S; Ding YB Med Oncol; 2012 Jun; 29(2):448-53. PubMed ID: 21347717 [TBL] [Abstract][Full Text] [Related]
23. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114 [TBL] [Abstract][Full Text] [Related]
24. [The relationship between the TSLC1 silencing and DNA methylation in human lung cancer cells]. Ming S; Gao J; Sun T Zhongguo Fei Ai Za Zhi; 2010 May; 13(5):464-9. PubMed ID: 20677643 [TBL] [Abstract][Full Text] [Related]
25. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis. Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757 [TBL] [Abstract][Full Text] [Related]
26. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines. Patel AC; Anna CH; Foley JF; Stockton PS; Tyson FL; Barrett JC; Devereux TR Carcinogenesis; 2000 Sep; 21(9):1691-700. PubMed ID: 10964101 [TBL] [Abstract][Full Text] [Related]
27. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells. Yang B; Yang ZG; Gao B; Shao GG; Li GH Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491 [TBL] [Abstract][Full Text] [Related]
28. Silencing of miR-137 by aberrant promoter hypermethylation in surgically resected lung cancer. Kang N; Choi SY; Kim YK; Yoo IeR; Han DH; Lee DS; Kim YS; Hong SH; Kang JH; Lee KY; Park JK; Sung SW; Park MS; Yim HW; Kim SJ; Park JY Lung Cancer; 2015 Aug; 89(2):99-103. PubMed ID: 26101014 [TBL] [Abstract][Full Text] [Related]
29. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Bailet O; Fenouille N; Abbe P; Robert G; Rocchi S; Gonthier N; Denoyelle C; Ticchioni M; Ortonne JP; Ballotti R; Deckert M; Tartare-Deckert S Cancer Res; 2009 Apr; 69(7):2748-56. PubMed ID: 19293188 [TBL] [Abstract][Full Text] [Related]
30. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer. Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719 [TBL] [Abstract][Full Text] [Related]
31. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Zöchbauer-Müller S; Fong KM; Geradts J; Xu X; Seidl S; End-Pfützenreuter A; Lang G; Heller G; Zielinski CC; Gazdar AF; Minna JD Oncogene; 2005 Sep; 24(41):6249-55. PubMed ID: 15940253 [TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757 [TBL] [Abstract][Full Text] [Related]
33. Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis. Shin SH; Lee KH; Kim BH; Lee S; Lee HS; Jang JJ; Kang GH Lab Invest; 2014 Dec; 94(12):1396-405. PubMed ID: 25310533 [TBL] [Abstract][Full Text] [Related]
34. Hypermethylation and clinicopathological significance of RASAL1 gene in gastric cancer. Chen H; Pan Y; Cheng ZY; Wang Z; Liu Y; Zhao ZJ; Fan H Asian Pac J Cancer Prev; 2013; 14(11):6261-5. PubMed ID: 24377515 [TBL] [Abstract][Full Text] [Related]
35. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832 [TBL] [Abstract][Full Text] [Related]
36. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas. Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237 [TBL] [Abstract][Full Text] [Related]
37. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer. Wang SH; Liu NH; Wang J; Bai H; Mao L Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105 [TBL] [Abstract][Full Text] [Related]
38. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Zhang Y; Miao Y; Yi J; Wang R; Chen L Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829 [TBL] [Abstract][Full Text] [Related]
39. Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells. Zuo S; Chen Y; Xu L; Tang Q; Zou S J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):281-4. PubMed ID: 17641842 [TBL] [Abstract][Full Text] [Related]
40. Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer. Park JY; Kim D; Yang M; Park HY; Lee SH; Rincon M; Kreahling J; Plass C; Smiraglia DJ; Tockman MS; Kim SJ Lung Cancer; 2013 Mar; 79(3):198-204. PubMed ID: 23273563 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]